Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

August 1, 2019

Study Completion Date

April 9, 2020

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Trifluridine/tipiracil hydrochloride (S 95005)

Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.

DRUG

Oxaliplatin

Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.

DRUG

Bevacizumab

Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.

DRUG

Nivolumab

Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.

Trial Locations (24)

1062

Magyar Honvedseg Egeszsegugyi Kozpont Onkologiai Osztaly, Budapest

1083

Semmelweis Egyetem I. sz. Belgyogyaszati Klinika - Klin. Farmakologiai Reszleg, Budapest

1090

Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie, Vienna

1122

"Orszagos Onkologiai Intezet B Belgyogyaszati-Onkologiai O. Es Klin. Farmakologiai O.", Budapest

13005

CHU de la Timone Hépato-Gastro-Entérologie - Oncology Digestive, Marseille

20246

Universitätsklinikum Hamburg-Eppendorf II. Medizin. Klinik und Poliklinik (Onkologie, Hämatologie), Hamburg

28007

Hospital Unviersitario Gregorio Marañon - Servicio de Oncología Médica, Madrid

28034

H. Univ. Ramon y Cajal - Servicio de Oncología Medica, Madrid

28050

H. Uni. Madrid Sanchinarro - CIOCC Servicio de Oncología, Madrid

35042

Centre Eugène Marquis Service d'Oncologie Médicale, Rennes

37134

Policlinico G.B. Rossi A.O.U.I. di Verona U.O.C. di Oncologia, Verona

38440

Klinikum Wolfsburg Medizinische Klinik II, Wolfsburg

44791

St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum Abteilung für Hämatologie und Onkologie, Bochum

46010

H. Clinico de Valencia INCLIVA - Departamento de Hematologia y Oncologia Medica 8ª planta, Valencia

47014

Ist.Scientifico Romagnolo per lo Studio e la Cura dei Tumori Department of Clinical Oncology, Meldola

75012

Hôpital Saint-Antoine Service d'Oncologie Médicale, Paris

75013

La Pitié Salpêtrière Centre Investigation clinique Paris Est, Paris

81377

Klinikum der Universität München Campus Großhadern, Medizinische Klinik und Poliklinik III, München

89081

Universitätsklinikum Ulm Zentrum für Innere Medizin, Klinik für Innere Medizin I, Ulm

94805

Institut Gustave Roussy DITEP, Villejuif

95122

ARNAS - Azienda Ospedaliera Garibaldi - Nesima Struttura Complessa di Oncologia Medica, Catania

08916

ICO Badalona. H. Germans Trials y Pujol - Servicio de Oncología médica, Badalona

08035

H. Valle de Hebrón - Servicio de Oncología - (VHIR), Barcelona

M20 4BX

Christie Hospital NHS Foundation Trust GI & Endocrine, Manchester

All Listed Sponsors
collaborator

ADIR, a Servier Group company

INDUSTRY

lead

Institut de Recherches Internationales Servier

OTHER

NCT02848443 - Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter